540 related articles for article (PubMed ID: 25220674)
1. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
Chang CY; Meyer RM; Reiff AO
Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
[TBL] [Abstract][Full Text] [Related]
2. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
[TBL] [Abstract][Full Text] [Related]
3. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
4. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
5. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
6. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
Klotsche J; Minden K; Niewerth M; Horneff G
Ann Rheum Dis; 2018 Jul; 77(7):996-1002. PubMed ID: 29453217
[TBL] [Abstract][Full Text] [Related]
7. Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD.
Bardan I; Fagerli KM; Sexton J; Kvien TK; Bakland G; Mielnik P; Hu Y; Lien G; Flatø B; Molberg Ø; Kristianslund EK; Aga AB
J Rheumatol; 2023 Apr; 50(4):538-547. PubMed ID: 36379571
[TBL] [Abstract][Full Text] [Related]
8. Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease.
Lovell DJ; Johnson AL; Huang B; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Schmidt KM; Mehta J; Wahezi DM; Ting TV; Verbsky JW; Eberhard BA; Spalding S; Chen C; Giannini EH
Arthritis Rheumatol; 2018 Sep; 70(9):1508-1518. PubMed ID: 29604189
[TBL] [Abstract][Full Text] [Related]
9. The BeSt way of withdrawing biologic agents.
Allaart CF; Lems WF; Huizinga TW
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
[TBL] [Abstract][Full Text] [Related]
10. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ;
J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
Aquilani A; Marafon DP; Marasco E; Nicolai R; Messia V; Perfetti F; Magni-Manzoni S; De Benedetti F
J Rheumatol; 2018 Jul; 45(7):956-961. PubMed ID: 29717035
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.
Kostik MM; Gaidar EV; Hynnes AY; Dubko MF; Masalova VV; Snegireva LS; Chikova IA; Isupova EA; Nikitina TN; Serogodskaya ED; Kalashnikova OV; Ravelli A; Chasnyk VG
Clin Exp Rheumatol; 2016; 34(4):714-8. PubMed ID: 27385618
[TBL] [Abstract][Full Text] [Related]
15. Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.
Tappeiner C; Schenck S; Niewerth M; Heiligenhaus A; Minden K; Klotsche J
Arthritis Care Res (Hoboken); 2016 Jan; 68(1):46-54. PubMed ID: 26212111
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
Foell D; Wulffraat N; Wedderburn LR; Wittkowski H; Frosch M; Gerss J; Stanevicha V; Mihaylova D; Ferriani V; Tsakalidou FK; Foeldvari I; Cuttica R; Gonzalez B; Ravelli A; Khubchandani R; Oliveira S; Armbrust W; Garay S; Vojinovic J; Norambuena X; Gamir ML; García-Consuegra J; Lepore L; Susic G; Corona F; Dolezalova P; Pistorio A; Martini A; Ruperto N; Roth J;
JAMA; 2010 Apr; 303(13):1266-73. PubMed ID: 20371785
[TBL] [Abstract][Full Text] [Related]
17. Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration.
Simonini G; Ferrara G; Pontikaki I; Scoccimarro E; Giani T; Taddio A; Meroni PL; Cimaz R
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1046-1051. PubMed ID: 28973842
[TBL] [Abstract][Full Text] [Related]
18. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.
Hissink Muller P; Brinkman DMC; Schonenberg-Meinema D; van den Bosch WB; Koopman-Keemink Y; Brederije ICJ; Bekkering PW; Kuijpers TW; Van Rossum M; van Suijlekom-Smit LWA; van den Berg JM; Boehringer S; Allaart CF; Ten Cate R
Ann Rheum Dis; 2019 Jan; 78(1):51-59. PubMed ID: 30309970
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?
Foell D; Frosch M; Schulze zur Wiesch A; Vogl T; Sorg C; Roth J
Ann Rheum Dis; 2004 Feb; 63(2):206-8. PubMed ID: 14722212
[TBL] [Abstract][Full Text] [Related]
20. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]